We are live on ! Find out more
GTHX

G1 Therapeutics, Inc. Common Stock
GTHX

Delisted

GTHX was delisted on the 17th of September, 2024.

Back to rankings

42 hedge funds and large institutions have $289M invested in G1 Therapeutics, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 14 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 3

250% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 4

66% more capital invested

Capital invested by funds: $174M → $289M (+$115M)

56% more funds holding

Funds holding: 27 → 42 (+15)

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

Holders
42
Holders Change
+15
Holders Change %
+55.56%
% of All Funds
1.05%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
18
Increased
14
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
+$14.5M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$10.5M
3
CAM
Cormorant Asset Management
Massachusetts
+$7.71M
4
BlackRock
BlackRock
New York
+$6.25M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$3.06M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$1.89M
2
RSCM
Rock Springs Capital Management
Maryland
-$1.33M
3
Goldman Sachs
Goldman Sachs
New York
-$1.06M
4
MIM
Monashee Investment Management
Massachusetts
-$787K
5
Victory Capital Management
Victory Capital Management
Texas
-$14.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$250K +$152K +8,244 +453%
TA
27
Teachers Advisors
New York
$238K +$177K +9,558 New
Goldman Sachs
28
Goldman Sachs
New York
$209K -$1.06M -57,190 -87%
Deutsche Bank
29
Deutsche Bank
Germany
$175K +$131K +7,072 New
Manulife (Manufacturers Life Insurance)
30
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$171K +$127K +6,894 New
AIG
31
American International Group
New York
$130K +$96.3K +5,214 New
Barclays
32
Barclays
United Kingdom
$118K +$72.4K +3,919 +490%
NFA
33
Nationwide Fund Advisors
Ohio
$89K +$66K +3,574 New
LTFS
34
Ladenburg Thalmann Financial Services
Florida
$57K +$42.5K +2,300 New
SO
35
STRS Ohio
Ohio
$57K +$42.5K +2,300 New
Legal & General Group
36
Legal & General Group
United Kingdom
$32K +$21.1K +1,141 +696%
TRCT
37
Tower Research Capital (TRC)
New York
$29K +$11.2K +607 +111%
Royal Bank of Canada
38
Royal Bank of Canada
Ontario, Canada
$16K +$11.8K +641 New
Wells Fargo
39
Wells Fargo
California
$14K +$10.1K +548 New
BNP Paribas Financial Markets
40
BNP Paribas Financial Markets
France
$11.1K +$8.26K +447 New
UBS Group
41
UBS Group
Switzerland
$10K -$9.14K -495 -55%
Bank of America
42
Bank of America
North Carolina
$9K +$6.74K +365 New
Millennium Management
43
Millennium Management
New York
– -$1.89M -108,145 Closed
MIM
44
Monashee Investment Management
Massachusetts
– -$787K -45,110 Closed
CCA
45
Catalyst Capital Advisors
New York
– -$6K -338 Closed
1
2

GTHX Hedge Fund Activity: Q3 2017 in Review

42 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q3 2017, worth a combined $289M — up 66% from $174M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new GTHX positions and 3 closed out — a net gain of 15 holders — while 14 added to existing stakes and 4 trimmed.

The largest buyer was Franklin Resources, adding an estimated $14.5M. The largest seller was Millennium Management, exiting entirely with an estimated $1.89M sold.

  • 42 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q3 2017, up from 27 in Q2 2017.
  • Funds reported $289M of G1 Therapeutics, Inc. Common Stock stock for Q3 2017, up 66% quarter-over-quarter.
  • 18 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q3 2017 and 3 closed out, a net change of +15 holders.
  • The largest G1 Therapeutics, Inc. Common Stock buyer in Q3 2017 was Franklin Resources, an estimated $14.5M added.
  • The largest G1 Therapeutics, Inc. Common Stock seller in Q3 2017 was Millennium Management, an estimated $1.89M sold.

Based on aggregated 13F filings for Q3 2017.